Inner Mongolia Furui Med Sci - Asset Resilience Ratio
Inner Mongolia Furui Med Sci (300049) has an Asset Resilience Ratio of 2.34% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 300049 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Inner Mongolia Furui Med Sci's Asset Resilience Ratio has changed over time. See Inner Mongolia Furui Med Sci net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Inner Mongolia Furui Med Sci's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300049 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥80.05 Million | 2.34% |
| Total Liquid Assets | CN¥80.05 Million | 2.34% |
Asset Resilience Insights
- Limited Liquidity: Inner Mongolia Furui Med Sci maintains only 2.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Inner Mongolia Furui Med Sci Industry Peers by Asset Resilience Ratio
Compare Inner Mongolia Furui Med Sci's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE |
Biotechnology | 84.34% |
|
3SBio Inc
F:83B |
Biotechnology | 10.64% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497 |
Biotechnology | 0.02% |
|
Novavax Inc
NASDAQ:NVAX |
Biotechnology | 53.87% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Inner Mongolia Furui Med Sci (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Inner Mongolia Furui Med Sci.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.43% | CN¥83.62 Million ≈ $12.24 Million |
CN¥3.44 Billion ≈ $503.22 Million |
-2.72pp |
| 2024-12-31 | 5.15% | CN¥157.50 Million ≈ $23.05 Million |
CN¥3.06 Billion ≈ $447.61 Million |
+1.59pp |
| 2023-12-31 | 3.55% | CN¥94.11 Million ≈ $13.77 Million |
CN¥2.65 Billion ≈ $387.41 Million |
-1.84pp |
| 2022-12-31 | 5.40% | CN¥136.20 Million ≈ $19.93 Million |
CN¥2.52 Billion ≈ $369.21 Million |
-0.38pp |
| 2021-12-31 | 5.78% | CN¥145.80 Million ≈ $21.34 Million |
CN¥2.52 Billion ≈ $369.43 Million |
+3.68pp |
| 2020-12-31 | 2.10% | CN¥48.00 Million ≈ $7.02 Million |
CN¥2.29 Billion ≈ $335.18 Million |
-3.95pp |
| 2019-12-31 | 6.05% | CN¥136.10 Million ≈ $19.92 Million |
CN¥2.25 Billion ≈ $329.28 Million |
+1.52pp |
| 2018-12-31 | 4.53% | CN¥96.68 Million ≈ $14.15 Million |
CN¥2.14 Billion ≈ $312.62 Million |
-2.19pp |
| 2017-12-31 | 6.72% | CN¥168.62 Million ≈ $24.67 Million |
CN¥2.51 Billion ≈ $367.37 Million |
+2.24pp |
| 2016-12-31 | 4.48% | CN¥107.80 Million ≈ $15.77 Million |
CN¥2.41 Billion ≈ $352.17 Million |
+0.22pp |
| 2015-12-31 | 4.26% | CN¥87.00 Million ≈ $12.73 Million |
CN¥2.04 Billion ≈ $298.65 Million |
+7.67pp |
| 2014-12-31 | -3.41% | CN¥-45.40 Million ≈ $-6.64 Million |
CN¥1.33 Billion ≈ $194.80 Million |
+0.12pp |
| 2013-12-31 | -3.53% | CN¥-40.29 Million ≈ $-5.90 Million |
CN¥1.14 Billion ≈ $167.08 Million |
-59.95pp |
| 2010-12-31 | 56.42% | CN¥448.91 Million ≈ $65.69 Million |
CN¥795.66 Million ≈ $116.43 Million |
-- |
About Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company also engages in the research and development and sales of diagnostic equipment and related medical services. It offers FibroScan series of liver fibrosis diagnostic instruments; FibroMeter series of blood test analysis tools for evaluating chronic liv… Read more